Recurrent hepatitis C after liver transplantation

Harshit Khara, Sandeep Mukherjee

Research output: Contribution to journalArticle

Abstract

Decompensated cirrhosis from hepatitis C virus (HCV) genotype 1 is the leading indication for liver transplantation in the United States, accounting for nearly 50% of all liver transplants. Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Since the first report of interferon for recurrent HCV treatment in 1996, there have been several reports in the literature of interferon-based therapies for this silent epidemic. However, these studies are limited by a paucity of randomized controlled trials. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful (

Original languageEnglish
Pages (from-to)91-99
Number of pages9
JournalImmunology, Endocrine and Metabolic Agents in Medicinal Chemistry
Volume10
Issue number2
StatePublished - 2010
Externally publishedYes

Fingerprint

Hepatitis C
Hepacivirus
Liver Transplantation
Interferons
Fibrosis
Liver
Ribavirin
Therapeutics
Randomized Controlled Trials
Transplantation
Genotype
Transplants
Population

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Pharmacology

Cite this

Recurrent hepatitis C after liver transplantation. / Khara, Harshit; Mukherjee, Sandeep.

In: Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, Vol. 10, No. 2, 2010, p. 91-99.

Research output: Contribution to journalArticle

@article{626dc82d7d744222897b4935a5c457e3,
title = "Recurrent hepatitis C after liver transplantation",
abstract = "Decompensated cirrhosis from hepatitis C virus (HCV) genotype 1 is the leading indication for liver transplantation in the United States, accounting for nearly 50{\%} of all liver transplants. Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30{\%} of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42{\%} per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Since the first report of interferon for recurrent HCV treatment in 1996, there have been several reports in the literature of interferon-based therapies for this silent epidemic. However, these studies are limited by a paucity of randomized controlled trials. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful (",
author = "Harshit Khara and Sandeep Mukherjee",
year = "2010",
language = "English",
volume = "10",
pages = "91--99",
journal = "Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry",
issn = "1871-5222",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Recurrent hepatitis C after liver transplantation

AU - Khara, Harshit

AU - Mukherjee, Sandeep

PY - 2010

Y1 - 2010

N2 - Decompensated cirrhosis from hepatitis C virus (HCV) genotype 1 is the leading indication for liver transplantation in the United States, accounting for nearly 50% of all liver transplants. Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Since the first report of interferon for recurrent HCV treatment in 1996, there have been several reports in the literature of interferon-based therapies for this silent epidemic. However, these studies are limited by a paucity of randomized controlled trials. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful (

AB - Decompensated cirrhosis from hepatitis C virus (HCV) genotype 1 is the leading indication for liver transplantation in the United States, accounting for nearly 50% of all liver transplants. Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Since the first report of interferon for recurrent HCV treatment in 1996, there have been several reports in the literature of interferon-based therapies for this silent epidemic. However, these studies are limited by a paucity of randomized controlled trials. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful (

UR - http://www.scopus.com/inward/record.url?scp=78649661075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649661075&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 91

EP - 99

JO - Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

JF - Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

SN - 1871-5222

IS - 2

ER -